Utilisation de la colchicine chez les patients insuffisants rénaux sévères et/ou dialysés : état des lieux des pratiques

Bausson, J.; Djededoua, H.; Scher, Florence; Paya, Dominique; Dory, Anne; Michel, B.; Fourtage, Marion; Gourieux, B.

doi:10.1016/j.nephro.2019.07.204

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 24 31 32 However, the prescription of colchicine in CKD patients is not uncommon in daily practice. 27 A pharmacokinetic study, established in the context of COVID-19, indicated that in the presence of impaired clearance >70%, the appropriate dosage might be 0.25 mg two times per day for the first 2 days, followed by 0.25 mg/day. 33 Our study is the first to assess the safety and efficacy profiles of low-dose colchicine regimens for treating crystal-induced arthritis flare in patients with severe CKD (G4–5).…”

Section: Discussionmentioning

confidence: 99%

“…26 Despite its contraindication, colchicine is regularly used in daily practice in our hospital. 27 Therefore, the aim of our study was to prospectively evaluate the prescription of colchicine and its efficacy and safety in managing crystal-induced arthritis flare (gout or CPPD) in patients with severe CKD (estimated glomerular filtration rate, eGFR <30 mL/ min) or on dialysis at the University Hospitals of Strasbourg, France.…”

Section: Rmd Open Rmd Open Rmd Openmentioning

confidence: 99%

See 1 more Smart Citation

Safety and efficacy of colchicine in crystal-induced arthritis flare in 54 patients with severe chronic kidney disease

Bausson,

Keller,

Von Hunolstein

et al. 2024

RMD Open

View full text Add to dashboard Cite

IntroductionColchicine, commonly used in gout flare, is contraindicated in severe chronic kidney disease (CKD) (estimated glomerular filtration rate <30 mL/min). However, in this context, there are few alternatives, and colchicine use persists. We evaluated the tolerance of colchicine and its efficacy in patients with severe CKD.Patients and methodsAll prescriptions of colchicine for managing crystal-induced arthritis flare (gout or calcium pyrophosphate deposition (CPPD) disease) in a hospitalised patient with severe CKD were screened from September 2020 to September 2021. After patient consent and treatment information, clinical and biological safety and efficacy data were prospectively collected from day 1 (D1) to D11.ResultsWe included 54 patients (median age 75 years (IQR 67–83)) with 62 colchicine prescriptions (cases). Twelve (22%) patients were on dialysis. The main reason for hospitalisation was heart failure (31.5%), acute renal failure (22.2%), infection (18.5%) or an acute joint episode (9.3%). In total, 59.3% of patients had diabetes. The prescriptions concerned 58 cases of gout flares, 1 case of CPPD and 3 cases of both. Initial colchicine dosages were ≤0.5 mg/day in 47/62 (75.8%) cases; no dosage exceeded 1 mg/day (median duration of 6 days (IQR 3–11)). Colchicine was well tolerated in 47/61 (77%) cases. No serious adverse event was reported. Colchicine was considered completely effective by the medical team in 48/58 (83%) of cases.ConclusionThe use of colchicine, at reduced doses, was mostly effective to treat crystal-induced arthritis flare in 54 patients with severe CKD and was well tolerated, without any serious adverse events.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Rmd Open Rmd Open Rmd Openmentioning

confidence: 99%